Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy

2018 ◽  
Vol 19 (7) ◽  
Author(s):  
Solange Peters ◽  
Stefan Zimmermann
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Anaplastic Lymphoma Kinase ◽  
Kinase Inhibitor ◽  
Inhibitor Therapy ◽  
First Line ◽  
Anaplastic Lymphoma ◽  
Tyrosine Kinase Inhibitor Therapy

NSCLC Patients Harbouring Rare or Complex EGFR Mutations Are More Often Smokers and Might Not Benefit from First-Line Tyrosine Kinase Inhibitor Therapy

Respiration ◽  
2017 ◽  
Vol 95 (3) ◽  
pp. 169-176 ◽  
Author(s):  
Diego Kauffmann-Guerrero ◽  
Rudolf Maria Huber ◽  
Simone Reu ◽  
Amanda Tufman ◽  
Pontus Mertsch ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Kinase Inhibitor ◽  
Inhibitor Therapy ◽  
Egfr Mutations ◽  
First Line ◽  
Tyrosine Kinase Inhibitor Therapy ◽  
Nsclc Patients

Cognitive dysfunction after withdrawal of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia

2016 ◽  
Vol 91 (11) ◽  
pp. E480-E481 ◽  
Author(s):  
Simone Claudiani ◽  
Jane F. Apperley ◽  
Simona Deplano ◽  
Jamshid Khorashad ◽  
Letizia Foroni ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Myeloid Leukaemia ◽  
Cognitive Dysfunction ◽  
Kinase Inhibitor ◽  
Inhibitor Therapy ◽  
Tyrosine Kinase Inhibitor Therapy
Sign in / Sign up

Export Citation Format

Share Document